In support of our observations, anti-KRASG12V TCR-redirected T cells conferred only reactivity to different human KRASG12V/HLA-A2 tumor cell lines when additionally loaded with KRASG12V peptide, whereas no response to endogenous KRASG12V/HLA-A2 complexes could be detected irrespectively of elevated HLA-A2 expression following IFN-γ pretreatment or engineered cancer cells overexpressing KRASG12V peptide [53]. This evidence concerns the gene IFNG and cancer.